PE20142399A1 - Compuestos de pirazol como inhibidores de sglt1 - Google Patents

Compuestos de pirazol como inhibidores de sglt1

Info

Publication number
PE20142399A1
PE20142399A1 PE2014001716A PE2014001716A PE20142399A1 PE 20142399 A1 PE20142399 A1 PE 20142399A1 PE 2014001716 A PE2014001716 A PE 2014001716A PE 2014001716 A PE2014001716 A PE 2014001716A PE 20142399 A1 PE20142399 A1 PE 20142399A1
Authority
PE
Peru
Prior art keywords
sglt1 inhibitors
compounds
pirazole
pirazole compounds
diazaespiro
Prior art date
Application number
PE2014001716A
Other languages
English (en)
Inventor
Fucheng Qu
Nathan Bryan Mantlo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428684&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142399(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20142399A1 publication Critical patent/PE20142399A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I), DONDE X ES LA FORMULA (II), (III), ENTRE OTROS. SON COMPUESTOS PREFERIDOS 4-{4-[(1E)-4-(1,8-DIAZAESPIRO[4.5]DEC-1-IL)BUT-1-EN-1-IL]-2-METILBENCIL}-5-(PROPAN-2-IL)-1H-PIRAZOL-3-IL BETA-D-GLUCOPIRANOSIDO; 4-{4-[(1E)-4-(2,8-DIAZAESPIRO[4.5]DEC-8-IL)BUT-1-EN-1-IL]-2-METILBENCIL}-5-(PROPAN-2-IL)-1H-PIRAZOL-3-IL BETA-D-GLUCOPIRANOSIDO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA EL TRATAMIENTO DE DIABETES TIPO 1.
PE2014001716A 2012-05-10 2013-05-02 Compuestos de pirazol como inhibidores de sglt1 PE20142399A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261645101P 2012-05-10 2012-05-10
US201361769221P 2013-02-26 2013-02-26

Publications (1)

Publication Number Publication Date
PE20142399A1 true PE20142399A1 (es) 2015-01-22

Family

ID=48428684

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001716A PE20142399A1 (es) 2012-05-10 2013-05-02 Compuestos de pirazol como inhibidores de sglt1

Country Status (43)

Country Link
US (2) US8697849B2 (es)
EP (1) EP2850084B1 (es)
JP (1) JP6148725B2 (es)
KR (1) KR101685779B1 (es)
AP (1) AP3593A (es)
AR (1) AR090806A1 (es)
AU (1) AU2013259946B2 (es)
BR (1) BR112014026198B1 (es)
CA (1) CA2869323C (es)
CL (1) CL2014002845A1 (es)
CO (1) CO7141429A2 (es)
CR (1) CR20140473A (es)
CY (1) CY1117912T1 (es)
DK (1) DK2850084T3 (es)
DO (1) DOP2014000250A (es)
EA (1) EA024207B1 (es)
EC (1) ECSP14026088A (es)
ES (1) ES2588835T3 (es)
GT (1) GT201400242A (es)
HK (1) HK1202542A1 (es)
HR (1) HRP20160804T1 (es)
HU (1) HUE030414T2 (es)
IL (1) IL235427A (es)
IN (1) IN2014DN07996A (es)
JO (1) JO3136B1 (es)
LT (1) LT2850084T (es)
MA (1) MA37501B1 (es)
ME (1) ME02405B (es)
MX (1) MX357058B (es)
MY (1) MY177326A (es)
NZ (1) NZ700356A (es)
PE (1) PE20142399A1 (es)
PH (1) PH12014502492A1 (es)
PL (1) PL2850084T3 (es)
PT (1) PT2850084T (es)
RS (1) RS55107B1 (es)
SG (1) SG11201407345QA (es)
SI (1) SI2850084T1 (es)
TN (1) TN2014000410A1 (es)
TW (1) TWI579295B (es)
UA (1) UA113086C2 (es)
WO (1) WO2013169546A1 (es)
ZA (1) ZA201407531B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
AR097890A1 (es) 2013-10-17 2016-04-20 Lilly Co Eli Compuestos de urea
JO3298B1 (ar) 2013-11-01 2018-09-16 Lilly Co Eli مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt
AR098670A1 (es) * 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
CN110054657B (zh) * 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法
CA3089092A1 (en) * 2018-04-04 2019-10-10 Japan Tobacco Inc. Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
EP4026564A4 (en) * 2019-09-04 2023-03-15 Japan Tobacco Inc. THERAPEUTIC OR PROPHYLACTIC PROCEDURE FOR DIABETES USING COMBINATION MEDICATION

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60009929T2 (de) 1999-08-31 2005-03-31 Kissei Pharmaceutical Co., Ltd., Matsumoto Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
US7087579B2 (en) 2001-02-26 2006-08-08 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
WO2002098893A1 (en) 2001-05-30 2002-12-12 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
US7375087B2 (en) 2002-08-08 2008-05-20 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
AU2007252432B2 (en) * 2006-05-19 2011-11-17 Taisho Pharmaceutical Co., Ltd. C-phenyl glycitol compound
RU2482122C2 (ru) 2007-12-27 2013-05-20 Киссеи Фармасьютикал Ко., Лтд. Моносебацинат производного пиразола
ES2397086T3 (es) 2009-02-23 2013-03-04 Taisho Pharmaceutical Co., Ltd. Compuestos de 4-isopropilfenil glucitol como inhibidores de SGLT1
BR112012007349A2 (pt) 2009-10-02 2019-09-24 Sanofi Sa uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas.
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1

Also Published As

Publication number Publication date
CN104284894B (zh) 2016-02-17
BR112014026198B1 (pt) 2021-02-02
EP2850084B1 (en) 2016-06-15
CA2869323C (en) 2016-03-29
ZA201407531B (en) 2016-05-25
EP2850084A1 (en) 2015-03-25
HK1202542A1 (zh) 2015-10-02
DOP2014000250A (es) 2014-11-30
KR20150001798A (ko) 2015-01-06
MA37501B1 (fr) 2016-11-30
US20130303471A1 (en) 2013-11-14
TN2014000410A1 (en) 2015-12-21
RS55107B1 (sr) 2016-12-30
MA37501A1 (fr) 2016-03-31
JO3136B1 (ar) 2017-09-20
JP6148725B2 (ja) 2017-06-14
PT2850084T (pt) 2016-08-02
SI2850084T1 (sl) 2016-07-29
CY1117912T1 (el) 2017-05-17
GT201400242A (es) 2015-08-27
ECSP14026088A (es) 2015-09-30
AP3593A (en) 2016-02-15
NZ700356A (en) 2016-06-24
WO2013169546A1 (en) 2013-11-14
IL235427A (en) 2016-06-30
MY177326A (en) 2020-09-11
PL2850084T3 (pl) 2017-05-31
JP2015516419A (ja) 2015-06-11
PH12014502492B1 (en) 2015-01-12
CO7141429A2 (es) 2014-12-12
EA024207B1 (ru) 2016-08-31
CR20140473A (es) 2014-11-21
AR090806A1 (es) 2014-12-10
AU2013259946B2 (en) 2015-09-10
US9296775B2 (en) 2016-03-29
MX357058B (es) 2018-06-25
HUE030414T2 (en) 2017-05-29
CA2869323A1 (en) 2013-11-14
MX2014013615A (es) 2015-02-12
BR112014026198A2 (pt) 2017-06-27
DK2850084T3 (en) 2016-09-12
EA201491852A1 (ru) 2015-02-27
CL2014002845A1 (es) 2015-01-30
IN2014DN07996A (es) 2015-05-01
LT2850084T (lt) 2016-09-12
TWI579295B (zh) 2017-04-21
KR101685779B1 (ko) 2016-12-12
UA113086C2 (xx) 2016-12-12
AU2013259946A1 (en) 2014-10-16
ES2588835T3 (es) 2016-11-07
US8697849B2 (en) 2014-04-15
ME02405B (me) 2016-09-20
CN104284894A (zh) 2015-01-14
HRP20160804T1 (hr) 2016-08-12
SG11201407345QA (en) 2014-12-30
TW201406773A (zh) 2014-02-16
US20140162967A1 (en) 2014-06-12
PH12014502492A1 (en) 2015-01-12
AP2014008044A0 (en) 2014-11-30

Similar Documents

Publication Publication Date Title
PE20142399A1 (es) Compuestos de pirazol como inhibidores de sglt1
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CO7180221A2 (es) Composiciones fungicidas
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
PE20150224A1 (es) Inhibidores del nampt
CO6670566A2 (es) Derivados de tetrahidro- pirido-pirimidina
NI201400043A (es) 4 - fenil - piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
CR20120296A (es) Nuevos compuestos de espiropiperidina
BR112015004111A2 (pt) novos derivados bicíclicos
PH12014502141A1 (en) New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists
EA201591527A1 (ru) Новые производные пиридина
GT201400111A (es) Triazolopiridinas sustituidas
EA201270216A1 (ru) Фармацевтический состав
TR201902788T4 (tr) Nörodejeneratif hastalıkların tedavisinde kullanışlı 1-arilkarbonil-4-oksi-piperidin bileşikleri.
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
PE20142359A1 (es) Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
BR102013003576B8 (pt) Método para produzir n-ciano-s-metil-s-[1-(6-tri-flúormetil-3-piridinil)etil]sulfilimina
PE20170914A1 (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa
MX360330B (es) Regimen de administracion para nitrocatecoles.
MX2022007670A (es) Compuestos antihelminticos que comprenden una estructura de quinolina.
EA201391797A1 (ru) 3-спироциклические пиперидиновые производные в качестве агонистов грелиновых рецепторов

Legal Events

Date Code Title Description
FG Grant, registration